Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EBV mRNA Vaccine in EBV-Positive HIV-Associated Lymphoma
NCT07563023Phase 1Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- May 2026
- Primary completion
- Dec 2027
01
Overview
Phase 1, open-label trial in HIV-associated lymphoma (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Dose Limiting Toxicity at 14 days and Extended Recommended Dose at 2 years. Planned start May 2026; status: not yet recruiting.
02
Conditions
HIV-associated lymphoma
Beyond the preview
Go deeper on NCT07563023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07563023.